Lansoprazole-associated collagenous colitis: Diffuse mucosal cloudiness mimicking ulcerative colitis

Chiba, Mitsuro; Sugawara, Takeshi; Tozawa, Haruhiko; Tsuda, Hidehiko; Abe, Toru; Tokairin, Takuo; Ono, Iwao; Ushiyama, Eriko; Freeman, Hugh J.
May 2009
World Journal of Gastroenterology;5/7/2009, Vol. 15 Issue 17, p2166
Academic Journal
Case Study
There have only been a few reports on lansoprazole-associated collagenous colitis. Colonic mucosa of collagenous colitis is known to be endoscopically normal. We present a case of collagenous colitis where the mucosa showed diffuse cloudiness mimicking ulcerative colitis. A 70-year-old woman developed watery diarrhea four to nine times a day. She had interstitial pneumonia at 67 and reflux esophagitis at 70 years. Lansoprazole 30 mg/d had been prescribed for reflux esophagitis for nearly 6 mo. Lansoprazole was withdrawn due to its possible side effect of diarrhea. Colonoscopy disclosed diffuse cloudiness of the mucosa which suggested ulcerative colitis. Consequently sulfasalazine 2 g/d was started. The patient's diarrhea dramatically disappeared on the following day. However, biopsy specimens showed subepithelial collagenous thickening and infiltration of inflammatory cells in the lamina propria, confirming the diagnosis of collagenous colitis. One month after sulfasalazine therapy was initiated, colonoscopic and histological abnormalities resolved completely. Five months later the diarrhea recurred. The findings on colonoscopy and histology were the same as before, confirming a diagnosis of collagenous colitis relapse. We found that the patient had begun to take lansoprazole again 3 mo ahead of the recent diarrhea. Withdrawal of lansoprazole promptly resolved the diarrhea. Endoscopic and histological abnormalities were also completely resolved, similar to the first episode. Retrospectively, the date of commencement of sulfasalazine and discontinuation of lansoprazole in the first episode was found to be the same. We conclude that this patient had lansoprazole-associated collagenous colitis.


Related Articles

  • Kids With Ulcerative Colitis May Find Relief.  // RN;Feb2007, Vol. 70 Issue 2, p58 

    The article reports on the safety and effectiveness of the anti-inflammatory drug Balsalazide (Colazal) in children with active ulcerative colitis based on a study in the U.S. The study found that about 45% of children given with higher dose and 37% provided with lower dose showed clinical...

  • Desflurane/sevoflurane.  // Reactions Weekly;8/13/2011, Issue 1364, p17 

    The article describes the case of a man who developed ulcerative colitis after receiving desflurane and sevoflurane.

  • Mesalazine.  // Reactions Weekly;1/9/2010 Part 2 of 2, Issue 1283, p64 

    The article describes a case of exacerbation of ulcerative colitis in a 30-year-old woman following treatment with a mesalazine enema.

  • Mesalazine.  // Reactions Weekly;8/10/2013, Issue 1465, p27 

    An abstract of the article "Mesalamine-induced transaminitis; a rare presentation.," by R. Shah and colleagues is presented.

  • Mercaptopurine.  // Reactions Weekly;1/5/2013, Issue 1433, p30 

    The article describes the cases of three patients who developed hepatotoxicity while receiving mercaptopurine for either ulcerative colitis or Crohn's disease.

  • Mercaptopurine.  // Reactions Weekly;8/11/2012, Issue 1414, p34 

    The article describes the case of a 56-year-old woman who developed pulmonary lymphomatoid granulomatosis (PLG) during treatment with mercaptopurine for ulcerative colitis.

  • Sulphasalazine retention enemas in ulcerative colitis: a double-blind trial. Palmer, K.R.; Goepel, J.R.; Holdsworth, C.D. // British Medical Journal (Clinical Research Edition);5/16/1981, Vol. 282 Issue 6276, p1571 

    Examines the therapeutic role of sulphasalazine retention enemas in ulcerative colitis in Great Britain. Assessment of benefit and side effects of the drug; Efficacy of rectal sulphasalazine in both severe and mild disease; Therapeutic action of the drug within the colon.

  • Corticosteroids/infliximab/Lactobacillus rhamnosus.  // Reactions Weekly;5/11/2013, Issue 1452, p14 

    The article presents a case study of a 17-year-old ulcerative colitis male patient who developed Lactobacillus bacteraemia after receiving treatment with a probiotic containing Lactobacillus rhamnosus and immunosuppressive therapy with methylprednisolone, infliximab, and prednisone.

  • Rituximab.  // Reactions Weekly;5/11/2013, Issue 1452, p37 

    The article presents a case study of a 38-year-old woman with ulcerative colitis, which developed while receiving rituximab for seronegative rheumatoid arthritis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics